Intralesional injection of hyaluronic acid compared with verapamil in acute phase of Peyronie’s disease: A prospective randomized clinical trial

References

• Carson C. Peyronie’s disease: new paradigm for the treatment of a unique cause of erectile dysfunction. Postgrad Med. 2020;132(sup4):4–8. doi: 10.1080/00325481.2020.1805865
   PubMedGoogle Scholar
• Chung PH, Han TM, Rudnik B, et al. Peyronie’s disease: what do we know and how do we treat it? Can J Urol. 2020;27:11–9.
   PubMedGoogle Scholar
• Sharma KL, Alom M, Trost L. The etiology of peyronie’s disease: Pathogenesis and genetic contributions. Sex Med Rev. 2020;8(2):314–23. doi: 10.1016/j.sxmr.2019.06.004
   PubMed Web of Science ®Google Scholar
• Brimley SC, Yafi FA, Greenberg J, et al. Review of management options for active-phase peyronie’s disease. Sex Med Rev. 2019;7(2):329–37. doi: 10.1016/j.sxmr.2018.09.007
   PubMed Web of Science ®Google Scholar
• Li EV, Esterquest R, Pham MN, et al. Peyronie’s disease: pharmacological treatments and limitations. Expert Rev Clin Pharmacol. 2021;14(6):703–13. doi: 10.1080/17512433.2021.1903873
   PubMed Web of Science ®Google Scholar
• Almeida JL, Felício J, Martins FE. Surgical planning and strategies for peyronie’s disease. Sex Med Rev. 2021;9(3):478–87. doi: 10.1016/j.sxmr.2020.07.008
   PubMed Web of Science ®Google Scholar
• Pyrgidis N, Yafi FA, Sokolakis I, et al. Assessment of conservative combination therapies for active and stable peyronie’s disease: a systematic review and meta-analysis. Eur Urol Focus. 2022;8(5):1520–30. doi: 10.1016/j.euf.2021.12.003
   PubMedGoogle Scholar
• Teloken P, Katz D. Medical management of peyronie’s disease: review of the clinical evidence. Med Sci (Basel). 2019;7(9):70–79. doi: 10.3390/medsci7090096
   PubMedGoogle Scholar
• Yousif A, Natale C, Hellstrom WJG. Conservative therapy for peyronie’s disease: a contemporary review of the literature. Curr Urol Rep. 2021;22(2):6–12. doi: 10.1007/s11934-020-01024-8
   PubMed Web of Science ®Google Scholar
• Hayat S, Brunckhorst O, Alnajjar HM, et al. A systematic review of non-surgical management in peyronieʼs disease. Int J Impot Res. 2022;35(6):89–105. doi: 10.1038/s41443-022-00633-w
   Web of Science ®Google Scholar
• Randhawa K, Shukla CJ. Non-invasive treatment in the management of Peyronie’s disease. Ther Adv Urol. 2019;11:175–89. doi: 10.1177/1756287218823671
   Web of Science ®Google Scholar
• Asali M, Asali M. Intralesional injection of the calcium channel blocker verapamil in peyronie’s disease: a critical review. Arch Ital Urol Androl. 2020;92(3):25–9. doi: 10.4081/aiua.2020.3.253
   PubMedGoogle Scholar
• Cai T, Tiscione D, Favilla V, et al. Oral administration and intralesional injection of hyaluronic acid versus intralesional injection alone in peyronie’s disease: results from a phase III study. World J Mens Health. 2021;39(3):526–32. doi: 10.5534/wjmh.200048
   PubMedGoogle Scholar
• Cocci A, Di Maida F, Cito G, et al. Comparison of intralesional hyaluronic acid vs. Verapamil for the treatment of acute phase peyronie’s disease: a prospective, open-label non-randomized clinical study. World J Mens Health. 2021;39(2):352–7. doi: 10.5534/wjmh.190108
   PubMedGoogle Scholar
• Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of peyronie’s disease. J Urol. 1994;151(6):1522–4. doi: 10.1016/S0022-5347(17)35291-6
   PubMed Web of Science ®Google Scholar
• Favilla V, Russo GI, Zucchi A, et al. Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie’s disease: preliminary results from a prospective, double-blinded, randomized study. Andrology. 2017;5:771–5. doi: 10.1111/andr.12368
   PubMed Web of Science ®Google Scholar
• Wayne GF, Cordon BH. Contemporary surgical and non-surgical management of Peyronie’s disease. Transl Androl Urol. 2018;7(4):603–617. doi: 10.21037/tau.2018.04.06
   PubMed Web of Science ®Google Scholar
• Mann U, Shiff B, Jain K, et al. Canadian provider perspectives on collagenase clostridium histolyticum for the treatment of peyronie’s disease and the impact of its discontinuation. Int J Impot Res. 2022;34(6):599–602. doi: 10.1038/s41443-021-00458-z
   PubMed Web of Science ®Google Scholar
• Ziegelmann M, Bole R, Avant R, et al. Conservatively managed peyronie’s disease-long-term survey results from patients undergoing nonsurgical and noninjection therapies. Urology. 2018;113:99–104. doi: 10.1016/j.urology.2017.11.012
   PubMed Web of Science ®Google Scholar
• Paulis G, De Giorgio G. Complete plaque regression in patients with peyronie’s disease after multimodal treatment with antioxidants: a report of 2 cases. Am J Case Rep. 2022;23:936–46. doi: 10.12659/AJCR.936146
   Web of Science ®Google Scholar
• Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for peyronie’s disease. J Urol. 2002;168(2):621–6. doi: 10.1016/S0022-5347(05)64691-5
   PubMed Web of Science ®Google Scholar
• Tuygun C, Ozok UH, Gucuk A, et al. The effectiveness of transdermal electromotive administration with verapamil and dexamethasone in the treatment of peyronie’s disease. Int Urol Nephrol. 2009;41(1):113–8. doi: 10.1007/s11255-008-9408-x
   PubMed Web of Science ®Google Scholar
• Heidari M, Nejadi JR, Ghate A, et al. Evaluation of intralesional injection of verapamil in treatment of Peyronie’s disease. J Pak Med Assoc. 2010;60:291–3. 4
   PubMed Web of Science ®Google Scholar
• Favilla V, Russo GI, Privitera S, et al. Combination of intralesional verapamil and oral antioxidants for Peyronie’s disease: a prospective, randomised controlled study. Andrologia. 2014;46:936–42. doi: 10.1111/and.12178
   PubMed Web of Science ®Google Scholar
• Schifano N, Capogrosso P, Antonini G, et al. The application of hyaluronic acid injections in functional and aesthetic andrology: a narrative review. Gels. 2023;9(2):25–36. doi: 10.3390/gels9020118
   Web of Science ®Google Scholar
• Vetrano M, Ranieri D, Nanni M, et al. Hyaluronic acid (HA), platelet-rich plasm and extracorporeal shock wave therapy (ESWT) promote human chondrocyte regeneration in vitro and ESWT-mediated increase of CD44 expression enhances their susceptibility to HA treatment. PloS One. 2019;14(6):218–40. doi: 10.1371/journal.pone.0218740
   Web of Science ®Google Scholar
• Gennaro R, Barletta D, Paulis G. Intralesional hyaluronic acid: an innovative treatment for peyronie’s disease. Int Urol Nephrol. 2015;47(10):1595–602. doi: 10.1007/s11255-015-1074-1
   PubMed Web of Science ®Google Scholar
• Zucchi A, Costantini E, Cai T, et al. Intralesional injection of hyaluronic acid in patients affected with peyronie’s disease: preliminary results from a prospective, multicenter, pilot study. Sexual Medicine. 2016;4(2):e85–e90. doi: 10.1016/j.esxm.2016.01.002
   Web of Science ®Google Scholar
• Au RY, Al-Talib TK, Au AY, et al. Avocado soybean unsaponifiables (ASU) suppress TNF-α, IL-1β, COX-2, iNOS gene expression, and prostaglandin E2 and nitric oxide production in articular chondrocytes and monocyte/macrophages. Osteoarthritis And Cartilage. 2007;15(11):1249–1255. doi: 10.1016/j.joca.2007.07.009
   PubMed Web of Science ®Google Scholar
• Zhang F, Qin F, Yuan J. Molecular mechanisms and current pharmacotherapy of peyronie’s disease: a review. Front Pharmacol. 2021;12:643–65. doi: 10.3389/fphar.2021.643641
   Google Scholar